<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663182</url>
  </required_header>
  <id_info>
    <org_study_id>Entecavir-01</org_study_id>
    <nct_id>NCT00663182</nct_id>
  </id_info>
  <brief_title>Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis</brief_title>
  <official_title>Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of Entecavir for patients With decompensated
      HBV-Related cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis B is one of the most widespread viral infections worldwide, potentially
      leading to liver cirrhosis and hepatocellular carcinoma. Previous studies demonstrated that
      patients with active viral replication, defined as the presence of detectable serum HBV-DNA
      or HBeAg, were at increased risk of developing progressive liver disease or death.The
      prognosis of decompensated cirrhosis resulting from chronic hepatitis B virus infection is
      poor. Anti-viral therapy in decompensated HBV-related cirrhosis has been recommended by the
      American Association for the Study of Liver Diseases. However, no high quality research on
      the effectiveness of anti-viral therapy in decompensated cirrhosis has been performed.

      Entecavir is a new nucleotide analogue, which has been proved effective in suppressing viral
      replication and decreasing the necroinflammatory response, was recommended as a first-line
      medication in AASLD guideline. Our purpose was to evaluate the effect of Entecavir for
      patients With decompensated HBV-Related cirrhosis. The main outcomes were liver function,
      HBV-DNA, disease progression, hepatocellular carcinoma, Child-Pugh score and the survival.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>liver function</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HBV-DNA</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease progression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatocellular carcinoma</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child-Pugh score</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>motality</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatitis B Virus</condition>
  <condition>Decompensated Cirrhosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with decompensated HBV-related cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Untreated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Entecavir 0.5 mg/d</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. over 16 years of age;

          2. evidence of active viral replication was documented by a positive test for HBV-DNA in
             serum;

          3. Liver cirrhosis was proven by ultrasound or CT;

          4. Decompensated cirrhosis was evidenced by a Child-Pugh score â‰¥ 7;

          5. patients had decompensation signs such as jaundice, ascites, variceal bleeding,
             hepatic encephalopathy

        Exclusion Criteria:

          1. evidence of hepatocellular carcinoma (suspicious foci on hepatic ultrasonography at
             screening or a rising serum level of alpha-fetoprotein)

          2. a serum alanine aminotransferase level more than 10 times the upper limit of normal

          3. coinfection with hepatitis C or D virus or human immunodeficiency virus

          4. other types of cirrhosis

          5. a history of anti-viral therapy

          6. a total bilirubin level higher than 170 mmol/L

          7. a history of malignant tumors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Changzheng Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7;351(15):1521-31.</citation>
    <PMID>15470215</PMID>
  </results_reference>
  <results_reference>
    <citation>Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat. 2005 Jul;12(4):386-92.</citation>
    <PMID>15985009</PMID>
  </results_reference>
  <results_reference>
    <citation>Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000 Jan;31(1):207-10.</citation>
    <PMID>10613747</PMID>
  </results_reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <last_update_submitted>April 22, 2008</last_update_submitted>
  <last_update_submitted_qc>April 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jian Shi</name_title>
    <organization>Shanghai Changzheng Hospital</organization>
  </responsible_party>
  <keyword>Entecavir</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>anti-viral</keyword>
  <keyword>therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

